Lenvatinib resistance management

Lenvatinib is approved to treat advanced renal cell carcinoma, differentiated thyroid cancer, endometrial cancer, and hepatocellular carcinoma. In addition, other cancer types have been trialled preclinically and clinically without FDA approval. The wide clinical application of lenvatinib illustrates its important therapeutic effect. Although large-scale resistance has not yet emerged clinically, there are increasing studies on resistance to lenvatinib.

The development of drug resistance often involves the activation of multiple signaling pathways. Therefore, by interfering with multiple targets simultaneously, the occurrence of drug resistance can be reduced. Combinations with other targeted therapies to inhibit multiple signaling pathways may be considered. Depending on the patient's specific circumstances, dosage adjustment of lenvatinib may be considered. Sometimes, lowering the dose can lessen the toxic side effects of a drug and delay the development of resistance. Give lenvatinib with other medicines to increase the effectiveness of treatment. For example, combining it with immunotherapy drugs such as PD-1 inhibitors (such as pembrolizumab) or cell cycle modulators (such as lapatinib) can improve treatment efficacy and reduce the risk of drug resistance.

Lenvatinib The original drug has been launched in China and has entered the scope of Class B medical insurance. The price of 4mg*30 tablets per box may be more than 3,000 yuan. Lenvatinib original drug currently on the market overseas, specifications 4mg*30 capsules, may cost more than 1,000 yuan per box (the price may fluctuate due to exchange rates). Lenvatinib generic drugs are also produced and marketed overseas. Their drug ingredients are basically the same as those of the original drugs sold domestically and abroad, but the price is cheaper. For example, the price of a box of 4mg*30 tablets produced by a Bangladesh pharmaceutical factory may be around RMB 800 (the price may fluctuate due to exchange rates).